Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.

Maryanne M Senna Arash MostaghimiM OhyamaR SinclairY DutroncW S WuG YuC ChiasseriniN SomaniK HolzwarthBrett A King

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)

Baricitinib demonstrated a high level of maintenance of efficacy over 104 weeks in patients with severe AA. Efficacy increased in Week-52 mixed responders, illustrating that long-term treatment is necessary to observe maximum benefit in some patients. No new safety signals were observed.

Keyphrases

end stage renal disease
ejection fraction
early onset
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
clinical trial
randomized controlled trial
patient reported outcomes
study protocol
drug induced
combination therapy
replacement therapy